PDLIM7 and Hodgkins lymphoma: Preliminary results of EBV specific CTL therapy in relapsed/refractory EBV-positive HL patients are encouraging [140] and, taken together, these findings have important implications in the improved design of immunotherapeutic strategies to boost LMP1/2-specific CTL activity.